The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 2 of the 18 sources its claims cite were checked for support.
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Open accessPublished version of a preprint
Abstract
A key public health need is to identify individuals at high risk for a given disease to enable enhanced screening or preventive therapies. Because most common diseases have a genetic component, one important approach is to stratify individuals based on inherited DNA variation1. Proposed clinical applications have largely focused on finding carriers of rare monogenic mutations at several-fold increased risk. Although most disease risk is polygenic in nature2–5, it has not yet been possible to use polygenic predictors to identify individuals at risk comparable to monogenic mutations. Here, we develop and validate genome-wide polygenic scores for five common diseases. The approach identifies 8.0, 6.1, 3.5, 3.2, and 1.5% of the population at greater than threefold increased risk for coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer, respectively. For coronary artery disease, this prevalence is 20-fold higher than the carrier frequency of rare monogenic mutations conferring comparable risk6. We propose that it is time to contemplate the inclusion of polygenic risk prediction in clinical care, and discuss relevant issues. Genome-wide polygenic risk scores derived from GWAS data for five common diseases can identify subgroups of the population with risk approaching or exceeding that of a monogenic mutation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
25 Own result · 9 Not checked yet · 7 Own method · 3 Own interpretation · 2 No basis given · 1 Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“GPSCAD performed substantially better than two previously published polygenic scores for coronary artery disease that included 50 and 49,310 variants, respectively (Supplementary Table 7 and Supplementary Fig. 1).17,18”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Supportedcites [17] Tada, H. et al. Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur. Heart J. 37, 561–567 (2016). source
The Methods (Modelling of genetic risk score) identify this paper’s GRS50 as a 50-SNP score for coronary heart disease, supporting its citation as the previously published 50-variant score. The comparison with GPSCAD is presented as the citing paper’s own analysis, not as a result attributed to this source. (LLM, conf=0.91)
- Supportedcites [18] Abraham, G. et al. Genomic prediction of coronary heart disease. Eur. Heart J. 37, 3267–3278 (2016). source
The citation identifies the previously published 49,310-variant score used as a comparator. Abraham et al. report generating that score in Abstract > Methods and results; the GPSCAD performance comparison is the citing authors’ own result, attributed to their supplementary table and figure. (LLM, conf=0.91)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, even for our middle-aged study population, practicing clinicians could not identify the 8% of individuals at ≥3-fold risk based on GPSCAD in the absence of genotype information (Supplementary Table 8).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.5% of the population at ≥3-fold risk and the top 1% had 3.30-fold risk. (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 6.1% of the population at ≥3-fold risk and the top 1% had 4.63-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.2% of the population at ≥3-fold risk and the top 1% had 3.87-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This predictor performed equivalently well in the testing dataset, with AUC of 0.81.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plainn = 288,978- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results for CAD generalized to four other diseases: risk increased sharply in the right tail of the GPS distribution (Figure 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In our testing dataset, 19.8% of participants were at ≥3-fold increased risk for at least one of the five diseases studied (Table 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 8
- Probably not a substantial claim. 6
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The predictors had AUC ranging from 0.79 – 0.81 in the validation set, with the best predictor (GPSCAD) involving 6,630,150 variants (Supplementary Table 1).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelationaln = 120,280- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Across the population, GPSCAD is normally distributed with the empirical risk of CAD rising sharply in the right tail of the distribution, from 0.8% in the lowest percentile to 11.1% in the highest percentile (Figure 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In order to analyze individuals with a relatively homogenous ancestry and owing to small percentages of non-British individuals, the present analysis was restricted to the white British ancestry individuals.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Whereas identifying carriers of rare monogenic mutations requires sequencing of specific genes and careful interpretation of the functional effects of mutations found, polygenic scores can be readily calculated for many diseases simultaneously, based on data from a single genotyping array.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Our validation and testing was performed in the UK Biobank population.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These initial efforts were hampered by three challenges: (i) the small size of initial genome-wide association studies (GWAS), which affected the precision of the estimated impact of individual variants on disease risk; (ii) limited computational methods for creating GPS; and (iii) lack of large datasets needed to validate and test GPS.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results above show that, for a number of common diseases, polygenic risk scores can now identify a substantially larger fraction of the population than found by rare monogenic mutations, at comparable or greater disease risk.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The vast majority of common disease occurs in individuals without rare monogenic mutations.
In the paper
“Individuals who volunteered for the UK Biobank tended to be more healthy than the general population;27”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [27] Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026–1034 (2017). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In both cases, it is important to recognize that the risk associated with a high polygenic score may not reflect a single underlying mechanism, but rather the combined influence of multiple pathways.28”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [28] Khera, A. V. & Kathiresan, S. Is coronary atherosclerosis one disease or many? Setting realistic expectations for precision medicine. Circulation 135, 1005–1007 (2017). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, we previously showed that a high polygenic risk for CAD may be offset by either of two interventions: adherence to a healthy lifestyle or cholesterol-lowering therapy with statin medications.19–21”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [19] Khera, A. V. et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med. 375, 2349–2358 (2016). source
- Not checked yetcites [20] Mega, J. L. et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385, 2264–2271 (2015). source
- Not checked yetcites [21] Natarajan, P. et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135, 2091–2101 (2017). source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“UK Biobank samples were not included in any of the five discovery GWAS studies.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Polygenic score derivation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“An important example is the presence of a familial hypercholesterolemia mutation in 0.4% of the population, which confers an up to 3-fold increased risk for coronary artery disease (CAD).6”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [6] Abul-Husn, N. S. et al. Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science 354, pii: aaf7000 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Another example is the p.E508K missense mutation in HNF1A, with carrier frequency of 0.1% of the general population and 0.7% of Latinos,8 which confers up to 5-fold increased risk for type 2 diabetes.9”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [8] Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). source
- Not checked yetcites [9] Estrada, K. et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA 311, 2305–2314 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The vast majority of common disease occurs in individuals without rare monogenic mutations.
“Although ascertainment of monogenic mutations can be highly relevant for carriers and their families, the vast majority of disease occurs in those without such mutations.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, integrated models of PRS together with other lifestyle and clinical factors have enabled clinicians to more accurately quantify the risk of heart attack for patients;”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This enthusiasm is driven by observations that a polygenic burden of LDL-increasing SNPs can confer monogenic-equivalent risk of cardiovascular disease, with polygenic scores improving clinical models for risk assessment and statin prescription that can reduce coronary heart disease and improve healthcare delivery efficiency5–7.”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using polygenic scores, it is now possible to combine information from millions of genomic variants to identify people whose overall polygenic risk of coronary artery disease is as high as that of patients with monogenic lipid disorders such as familial hypercholesterolemia [23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, they have contributed new approaches to risk prediction for adverse phenotypes related to heart disease [21–23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
In the citing paper
“As described below, findings from GWAS have increasing translational impact through identification of novel therapeutic targets67, prioritization (and deprioritization) of existing ones68 and development of polygenic scores that quantify individual genetic risk69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“The development of robust polygenic scores for several common diseases has been catalysed by more precise per-variant effect estimates from larger GWAS datasets, improved algorithms for combining information across millions of single-nucleotide polymorphisms, and large-scale biobanks that support score validation69,146,147.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“For example, a genome-wide polygenic score for heart attack, incorporating 6.6 million variants, indicates that 5% of European-descent individuals have a risk of future cardiac events equivalent to that seen in those with less frequent monogenic forms of hypercholesterolaemia69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“This paper used large-scale genetic data to demonstrate the clinical potential of the polygenic scores that can be constructed for many common diseases, emphasizing that, in some situations, the lifetime risk of disease for those with the highest scores approaches that of established monogenic disease.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Statistical analysis within the testing dataset
“For each disease, the GPS with the best discriminative capacity in the testing dataset was calculated in the testing dataset of 288,278 participants”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Self-citationVos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Second-generation PLINK: rising to the challenge of larger and richer datasets
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015) · Gigascience · doi:10.1186/s13742-015-0047-8 · Cited by 12,709
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citationVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
Self-citationCommon polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,006
Commentary: Novel strategies and new tools to curtail the health effects of pesticides
Benbrook, C., Perry, M. J., Belpoggi, F., Landrigan, P. J., Perro, M., Mandrioli, D., Antoniou, M. N., Winchester, P., & Mesnage, R. (2021) · Environmental Health · doi:10.1186/s12940-021-00773-4 · Cited by 24
Small, A. M., Melloni, G. E. M., Kamanu, F. K., Bergmark, B. A., Bonaca, M. P., O’Donoghue, M. L., Giugliano, R. P., Scirica, B. M., Bhatt, D., Antman, E. M., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0011 · Cited by 23
Self-citationApplying polygenic risk score methods to pharmacogenomics GWAS: challenges and opportunities
Zhai, S., Mehrotra, D. V., & Shen, J. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad470 · Cited by 23
Siermann, M., Valcke, O., Vermeesch, J. R., Raivio, T., Tšuiko, O., & Borry, P. (2024) · Social Science & Medicine · doi:10.1016/j.socscimed.2024.116599 · Cited by 23
Pharmacogenomics polygenic risk score: Ready or not for prime time?
Singh, S., Stocco, G., Theken, K. N., Dickson, A. L., Feng, Q., Karnes, J. H., Mosley, J. D., & Rouby, N. M. E. (2024) · Clinical and Translational Science · doi:10.1111/cts.13893 · Cited by 25
Comparison of methods for building polygenic scores for diverse populations
Gunn, S., Wang, X., Posner, D. C., Cho, K., Huffman, J. E., Gaziano, J. M., Wilson, P. W. F., Sun, Y. V., Peloso, G. M., & Lunetta, K. L. (2024) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2024.100355 · Cited by 25
Diabetes mellitus polygenic risk scores: heterogeneity and clinical translation
Ortega, H. I., Udler, M. S., Gloyn, A. L., & Sharp, S. A. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01132-w · Cited by 26
Precision Medicine: Personalizing Healthcare by Bridging Aging, Genetics, and Global Diversity
Edvardsson, M., & Heenkenda, M. K. (2025) · Healthcare · doi:10.3390/healthcare13131529 · Cited by 24
Influence of Genetic Interactions on Polygenic Prediction
Dai, Z., Long, N., & Huang, W. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400812 · Cited by 25
Prediagnostic breast milk DNA methylation alterations in women who develop breast cancer
Salas, L. A., Lundgren, S., Browne, E. P., Punska, E. C., Anderton, D. L., Karagas, M. R., Arcaro, K. F., & Christensen, B. C. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz301 · Cited by 23
Rezaee, M., Putrenko, I., Takeh, A., Ganna, A., & Ingelsson, E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235758 · Cited by 23
Trevino, C. E., Holleman, A. M., Corbitt, H., Maslen, C. L., Rosser, T. C., Cutler, D. J., Johnston, H. R., Rambo‐Martin, B. L., Oberoi, J., Dooley, K. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74650-4 · Cited by 23
Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts*
Steinberg, J., Iles, M. M., Lee, J. Y., Wang, X., Law, M. H., Smit, A. K., Nguyen‐Dumont, T., Giles, G. G., Southey, M. C., Milne, R. L., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20956 · Cited by 23
Augustine, T., Al‐Aghbar, M. A., Alkowari, M. K., Espino‐Guarch, M., & van Panhuys, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.822324 · Cited by 26
Choe, E. K., Shivakumar, M., Lee, S. M., Verma, A., & Kim, D. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01168-2 · Cited by 26
Ramírez, J., van Duijvenboden, S., Young, W. J., Tinker, A., Lambiase, P. D., Orini, M., & Munroe, P. B. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003441 · Cited by 23
Ed‐Driouch, C., Mars, F., Gourraud, P., & Dumas, C. (2022) · Sensors · doi:10.3390/s22218313 · Cited by 23
AI-based multi-PRS models outperform classical single-PRS models
Klau, J. H., Maj, C., Klinkhammer, H., Krawitz, P. M., Mayr, A. J., Hillmer, A. M., Schumacher, J., & Heider, D. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1217860 · Cited by 23
An evolutionary perspective on complex neuropsychiatric disease
McClellan, J., Zoghbi, A. W., Buxbaum, J. D., Cappi, C., Crowley, J. J., Flint, J., Grice, D. E., Gülsüner, S., Iyegbe, C. O., Jain, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.10.037 · Cited by 25
Rashkin, M. D., Bowes, J., Dunaway, K. W., Dhaliwal, J. K., Loomis, E. W., Riffle, S., Washington, N. L., Ziegler, C., Lu, J. T., & Levin, E. (2019) · Journal of Genetic Counseling · doi:10.1002/jgc4.1123 · Cited by 23
Screening and management of familial hypercholesterolemia
Santos, R. D. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000660 · Cited by 23
Möller, M., & Kinnear, C. J. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000672 · Cited by 23
Mojarad, B. A., Yin, Y., Manshaei, R., Backstrom, I., Costain, G., Heung, T., Merico, D., Marshall, C. R., Bassett, A. S., & Yuen, R. K. C. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01211-2 · Cited by 24
Evolution and Outcomes of Premature Coronary Artery Disease
Smith, C. L., Seigerman, M. E., Adusumalli, S., Giri, J. S., Fiorilli, P. N., Kolansky, D. M., & Kobayashi, T. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01457-8 · Cited by 23
Concordance of a High Polygenic Score Among Relatives
Reid, N., Brockman, D., Leonard, C. E., Pelletier, R. C., & Khera, A. V. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003262 · Cited by 23
Self-citationXPXP: improving polygenic prediction by cross-population and cross-phenotype analysis
Xiao, J., Cai, M., Hu, X., Wan, X., Chen, G., & Yang, C. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac029 · Cited by 24
Olmastroni, E., Gazzotti, M., Arca, M., Averna, M., Pirillo, A., Catapano, A. L., Casula, M., Bertolini, S., Calandra, S., Tarugi, P., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023668 · Cited by 23
Polygenic scores: Are they a public health hazard?
Baverstock, K. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.08.004 · Cited by 24
IPRS: Leveraging Gene-Environment Interaction to Reconstruct Polygenic Risk Score
Tang, Y., You, D., Yi, H., Yang, S., & Zhao, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.801397 · Cited by 22
Arena, G., Landoulsi, Z., Großmann, D., Payne, T., Vitali, A., Delcambre, S., Baron, A., Antony, P. M. A., Boussaad, I., Bobbili, D. R., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26949 · Cited by 22
Polygenic Risk Is Associated With Long-Term Coronary Plaque Progression and High-Risk Plaque
Nurmohamed, N. S., Shim, I., Gaillard, E. L., Ibrahim, S., Bom, M. J., Earls, J. P., Min, J. K., Planken, R. N., Choi, A. D., Natarajan, P., et al. (2024) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.06.015 · Cited by 22
Self-citationBraffett, B. H., Bebu, I., Lorenzi, G. M., Martin, C. L., Perkins, B. A., Gubitosi‐Klug, R., & Nathan, D. M. (2025) · Diabetes Care · doi:10.2337/dc24-2885 · Cited by 23
Use of a Polygenic Risk Score Improves Prediction of Myocardial Injury After Non-Cardiac Surgery
Douville, N. J., Surakka, I. L., Leis, A. M., Douville, C. B., Hornsby, W., Brummett, C. M., Kheterpal, S., Willer, C. J., Engoren, M., & Mathis, M. R. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002817 · Cited by 22
Thayer, T. E., Levinson, R. T., Huang, S., Assad, T. R., Farber‐Eger, E. H., Wells, Q. S., Mosley, J. D., & Brittain, E. L. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.07.038 · Cited by 22
Figtree, G. A., Vernon, S. T., & Nicholls, S. J. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa030 · Cited by 22
Connecting the epigenome, metabolome and proteome for a deeper understanding of disease
Suhre, K., & Zaghlool, S. B. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13306 · Cited by 23
Wang, Y.-C., Wu, Y., Choi, J. Y., Allington, G., Zhao, S., Khanfar, M., Yang, K., Fu, P.-Y., Wrubel, M., Yu, X., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020175 · Cited by 23
Low depression frequency is associated with decreased risk of cardiometabolic disease
Honigberg, M. C., Ye, Y., Dattilo, L. W., Sarma, A. A., Scott, N. S., Smoller, J. W., Zhao, H., Wood, M. J., & Natarajan, P. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00011-7 · Cited by 23
Self-citationGarcía‐Etxebarria, K., Merino, O., Gaite-Reguero, A., Rodrigues, P. M., Herrarte, A., Etxart, A., Ellinghaus, D., Alonso‐Galán, H., Franke, A., Marigorta, U. M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07401-2 · Cited by 22
Ashenhurst, J. R., Sazonova, O. V., Svrchek, O., Detweiler, S., Kita, R., Babalola, L., McIntyre, M. H., Aslibekyan, S. W., Fontanillas, P., Shringarpure, S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.871260 · Cited by 22
Hu, X., Qiao, D., Kim, W., Moll, M. R., Balte, P., Lange, L. A., Bartz, T. M., Kumar, R., Li, X., Yu, B., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.03.007 · Cited by 21
Vinci, A., Ingravalle, F., Bardhi, D., Cesaro, N., Frassino, S., Licata, F., & Valvano, M. (2022) · Biomedicines · doi:10.3390/biomedicines10102439 · Cited by 22
Nguyen, D., Tran, T. T. H., Tran, M. H., Tran, K., Pham, D., Dương, N. T., Nguyen, Q. H., & Vo, N. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-22215-y · Cited by 22
The immunogenetics of tuberculosis (TB) susceptibility
Sima, C. A. A. N., Smith, D., Petersen, D. C., Schurz, H., Uren, C., & Möller, M. (2022) · Immunogenetics · doi:10.1007/s00251-022-01290-5 · Cited by 22
Xin, J., Jiang, X., Li, H., Chen, S., Zhang, Z., Wang, M., Gu, D., Du, M., & Christiani, D. C. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104454 · Cited by 22
Human Genomics of COVID-19 Pneumonia: Contributions of Rare and Common Variants
Cobat, A., Zhang, Q., Effort, C. H. G., Abel, L., Casanova, J., & Fellay, J. (2023) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-020222-021705 · Cited by 25
Tuning parameters for polygenic risk score methods using GWAS summary statistics from training data
Jiang, W., Chen, L., Girgenti, M. J., & Zhao, H. (2024) · Nature Communications · doi:10.1038/s41467-023-44009-0 · Cited by 25
Review article: Prevention of inflammatory bowel disease—The path forward
Bronze, S. M. T., Agrawal, M., Colombel, J., Torres, J., & Ungaro, R. C. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18263 · Cited by 22
Clinical relevance of genome‐wide polygenic score may be less than claimed
Curtis, D. (2019) · Annals of Human Genetics · doi:10.1111/ahg.12302 · Cited by 22
Value of genetic testing in the prevention of coronary heart disease events
Hynninen, Y., Linna, M., & Vilkkumaa, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210010 · Cited by 25
Fiorica, P. N., & Wheeler, H. E. (2019) · PeerJ · doi:10.7717/peerj.7778 · Cited by 23
The positive end of the polygenic score distribution for ADHD: a low risk or a protective factor?
Li, J. J. (2019) · Psychological Medicine · doi:10.1017/s0033291719003039 · Cited by 24
Mefford, J., Park, D. S., Zheng, Z., Ko, A., Ala‐Korpela, M., Laakso, M., Pajukanta, P., Yang, J., Witte, J. S., & Zaitlen, N. (2020) · Journal of Computational Biology · doi:10.1089/cmb.2019.0325 · Cited by 22
Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence
Dasa, O., Pepine, C. J., & Pearson, T. A. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.11.014 · Cited by 23
Precision Medicine Approaches to Vascular Disease
Miller, C. L., Kontorovich, A., Hao, K., Ma, L., Iyegbe, C. O., Björkegren, J., & Kovacic, J. C. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.001 · Cited by 24
Barroso, I. (2021) · Diabetologia · doi:10.1007/s00125-021-05575-4 · Cited by 22
Timmerman, N., de Kleijn, D. P. V., de Borst, G. J., den Ruijter, H. M., Asselbergs, F. W., Pasterkamp, G., Haitjema, S., & van der Laan, S. W. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.04.013 · Cited by 22
Predicting Age of Conversion to CAC >0
Blaha, M. J. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.12.007 · Cited by 22
Reeskamp, L. F., Shim, I., Dron, J. S., Ibrahim, S., Tromp, T. R., Fahed, A. C., Patel, A. P., Hutten, B. A., Stroes, E. S. G., Hovingh, G. K., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100662 · Cited by 21
Self-citationThe Interface of Therapeutics and Genomics in Cardiovascular Medicine
Magavern, E. F., Kaski, J. C., Turner, R. M., Janmohamed, A., Borry, P., & Pirmohamed, M. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07149-3 · Cited by 22
Polygenic risk scores in psychiatry – Large potential but still limited clinical utility
Smeland, O. B., & Andreassen, O. A. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.05.007 · Cited by 21
A Web Portal for Communicating Polygenic Risk Score Results for Health Care Use—The P5 Study
Marjonen, H., Marttila, M. M., Paajanen, T. I., Vornanen, M., Brunfeldt, M., Joensuu, A., Halmesvaara, O., Aro, K., Alanne-Kinnunen, M., Jousilahti, P., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.763159 · Cited by 21
Carter, A. R., Harrison, S., Gill, D., Smith, G. D., Taylor, A. E., Howe, L. D., & Davies, N. M. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac002 · Cited by 22
Cecchi, A. C., Drake, M., Campos, C. S., Howitt, J., Medina, J., Damrauer, S. M., Shalhub, S., Milewicz, D. M., Case, M., Cotter, N. E., et al. (2022) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2022.02.003 · Cited by 21
Should preimplantation genetic testing for polygenic disease be offered to all – or none?
Treff, N. R., Savulescu, J., de Melo‐Martín, I., SHULMAN, L. P., & Feinberg, E. C. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.03.017 · Cited by 21
Genetic and modifiable risk factors combine multiplicatively in common disease
Pang, S., Yengo, L., Nelson, C. P., Bourier, F. J., Zeng, L., Li, L., Kessler, T., Erdmann, J., Mägi, R., Läll, K., et al. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02081-4 · Cited by 21
Gerussi, A., Verda, D., Cappadona, C., Cristoferi, L., Bernasconi, D. P., Bottaro, S., Carbone, M., Muselli, M., Invernizzi, P., Asselta, R., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101587 · Cited by 22
Diversity in Polygenic Risk of Primary Open-Angle Glaucoma
Bailey, J. N. C., Funk, K. L., Cruz, L. A., Waksmunski, A. R., Kinzy, T. G., Wiggs, J. L., & Hauser, M. A. (2022) · Genes · doi:10.3390/genes14010111 · Cited by 21
Building a precision medicine infrastructure at a national level: The Swedish experience
Edsjö, A., Lindstrand, A., Gisselsson, D., Mölling, P., Friedman, M., Cavelier, L. B., Johansson, M., Ehrencrona, H., Fagerqvist, T., Strid, T., et al. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.3 · Cited by 22
Park, J. K., & Lu, C. Y. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040573 · Cited by 23
Hu, J., Chen, X., Luo, Y., Yang, J., Zeng, Q., Luo, W., Shu, X., Cheng, Q., Gong, L., Wang, Z., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155593 · Cited by 21
DeForest, N., Kavitha, B., Hu, S., Isaac, R., Krohn, L., Wang, M., Du, X., De Arruda Saldanha, C., Gylys, J., Merli, E., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100339 · Cited by 21
Self-citationMujwara, D., Kintzle, J., Domenico, P. D., Busby, G., & Bottà, G. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1139496 · Cited by 17
Polygenic risk scores associate with blood pressure traits across the lifespan
Øvretveit, K., Ingeström, E., Spitieris, M., Tragante, V., Wade, K. H., Thomas, L. F., Wolford, B. N., Wisløff, U., Gudbjartsson, D. F., Hólm, H., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad365 · Cited by 21
Ishikawa, Y., Tanaka, N., Asano, Y., Kodera, M., Shirai, Y., Akahoshi, M., Hasegawa, M., Matsushita, T., Saito, K., Motegi, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44541-z · Cited by 21
Kim, N. Y., Lee, H., Kim, S. H., Kim, Y., Lee, H., Lee, J., Kwak, S. H., & Lee, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-55313-0 · Cited by 21
Polygenic Risk of Epilepsy and Poststroke Epilepsy
Rivier, C. A., Rivier, C. A., Misra, S., Zelano, J., Mazumder, R., Sansing, L. H., de Havenon, A., Hirsch, L. J., Liebeskind, D. S., Gilmore, E. J., et al. (2024) · Stroke · doi:10.1161/strokeaha.124.047459 · Cited by 21
Precision Preventive Medicine—Ready for Prime Time?
Greenland, P., & Hassan, S. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0142 · Cited by 21
Adding value to real-world data: the role of biomarkers
Plant, D., & Barton, A. C. (2019) · Rheumatology · doi:10.1093/rheumatology/kez113 · Cited by 21
Evolution of approaches to identify melanoma missing heritability
Dalmasso, B., & Ghiorzo, P. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1738221 · Cited by 21
Utility and Diversity: Challenges for Genomic Medicine
Burke, W. (2021) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-120220-082640 · Cited by 22
Polygenic risk scores: how much do they add?
Christoffersen, M., & Tybjærg‐Hansen, A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000759 · Cited by 22
Lu, H., Wang, T., Zhang, J., Zhang, S., Huang, S., & Zeng, P. (2021) · Human Genetics · doi:10.1007/s00439-021-02299-8 · Cited by 21
Polygenic Score for Physical Activity Is Associated with Multiple Common Diseases
Sillanpää, E., Palviainen, T., Ripatti, S., Kujala, U. M., & Kaprio, J. A. (2021) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002788 · Cited by 24
Adaptive Sampling Strategies to Construct Equitable Training Datasets
Cai, W., Encarnación, R., Chern, B., Corbett‐Davies, S., Bogen, M., Bergman, S., & Goel, S. (2022) · ACM Conference on Fairness, Accountability, and Transparency (FAccT) · doi:10.1145/3531146.3533203 · Cited by 21
1H-NMR metabolomics-based surrogates to impute common clinical risk factors and endpoints
Bizzarri, D., Reinders, M. J. T., Beekman, M., Slagboom, P. E., Bbmri-Nl, & van den Akker, E. B. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103764 · Cited by 21
Are polygenic risk scores ready for the cancer clinic?—a perspective
Klein, R. J., & Gumus, Z. H. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-698 · Cited by 21
Dowaidar, M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/rvm3z · Cited by 25
AI in Healthcare: Transforming Medicine with Intelligence
Sharma, S., Tyagi, P., Srivastava, A., Rajput, N. K., Garg, P. K., & Kumari, M. (2025) · Global Conference on AI Research and Emerging Developments (G-CARED) · doi:10.63169/gcared2025.p4 · Cited by 21
Han, H. Y., Masip, G., Meng, T., & Nielsen, D. E. (2024) · Journal of Nutrition · doi:10.1016/j.tjnut.2024.10.014 · Cited by 20
Optimization of multi-ancestry polygenic risk score disease prediction models
Lerga-Jaso, J., Terpolovsky, A., Novković, B., Osama, A., Manson, C., Bohn, S., Marino, A. D., Kunitomi, M., & Yazdi, P. G. (2025) · Scientific Reports · doi:10.1038/s41598-025-02903-1 · Cited by 21
Proteomic Signatures for Risk Prediction of Atrial Fibrillation
Park, H., Norby, F. L., Kim, D., Jang, E., Yu, H. T., Kim, T., Uhm, J., Sung, J., Pak, H., Lee, M., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.073457 · Cited by 20
Use of Polygenic Risk Scores of Nicotine Metabolism in Predicting Smoking Behaviors
Chen, L., Hartz, S. M., Baker, T. B., Ma, Y., Saccone, N. L., & Bierut, L. J. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0081 · Cited by 20
Artificial Intelligence in Oncology Drug Discovery and Development
Cassidy, J. W., & Taylor, B. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.88376 · Cited by 21
Hadley, T. D., Agha, A. M., & Ballantyne, C. M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00915-6 · Cited by 21
Shelly, S., Mills, J. R., Dubey, D., McKeon, A. B., Ζεκερίδου, Α., Pittock, S. J., Harper, C. M., Naddaf, E., Milone, M., Mandrekar, J. N., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012050 · Cited by 20
Hu, G., Gao, F., Wang, G., Fang, Y., Guo, Y., Zhou, J., Gu, Y., Zhang, C., Gao, N., Wen, Q., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03038-3 · Cited by 20
Xu, J., Resurreccion, W. K., Shi, Z., Wei, J., Wang, C., Zheng, S. L., Hulick, P. J., Ross, A. E., Pavlovich, C. P., Helfand, B. T., et al. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00458-6 · Cited by 20
Polygenic risk, population structure and ongoing difficulties with race in human genetics
Kaplan, J. M., & Fullerton, S. M. (2022) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2020.0427 · Cited by 20
Shared components of heritability across genetically correlated traits
Ballard, J. L., & O’Connor, L. J. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.04.003 · Cited by 22
Metadata
- Authors
- Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., & Kathiresan, S.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Kathiresan, Sekar
- ORCID
- Venue
- Nature Genetics
- Published
- 2018-08-13
- Volume
- 50
- Issue
- 9
- Pages
- 1219-1224
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC6128408
- OpenAlex
- W2886752110
- Semantic Scholar
- d5eb49c11d070114e2ff46224099895c6b4b1558
- Cited by
- 2,953
- References
- 46
- Citations by year
- 2026: 276 · 2025: 290 · 2024: 363 · 2023: 362 · 2022: 433 · 2021: 411 · 2020: 451 · 2019: 307 · 2018: 57
- FWCI
- 189.86
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, other-oa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Doris Duke Charitable Foundation (2014105)
- Massachusetts General Hospital (HL007208)
- Harvard Catalyst (TR001100)
- Vertex Pharmaceuticals
- KR Foundation
- National Institutes of Health (KL2TR001100, HL0-07734, HL007208, T32-HL007734)
- National Heart, Lung, and Blood Institute (R01HL127564, HL007208, HL127564, R01HL128914, T-32HL007734, K08HL140203, HL007734, K23HL114724, K24HL105780, R01HL142711, R01HL092577, T32HL007208, R01HL139731)
- National Human Genome Research Institute (UM1HG008895)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and phenotypic traits in livestock
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- polygenic risk score, monogenic mutations, common diseases, coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, breast cancer, high-risk individuals, clinical risk stratification
- MeSH terms
- Adult, Aged, Disease, Female, Humans, Male, Middle Aged, Mutation, Risk Factors, Genetic Predisposition to Disease, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
